1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. CONNECT BIOPHARMA HOLDINGS LTD - ADR
Connect Biopharma Holdings Ltd - ADR
XNAS: CNTB
0.87-0.01(-1.14%)
1.0M
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Connect Biopharma Holdings Ltd (ADR) quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Connect Biopharma Holdings Ltd (ADR) share price target, revenues, EPS, net income and more

Connect Biopharma Holdings Ltd (ADR) quarterly results: revenue, profit, and P&L – 13 quarter history

  • POSITIVE

    Quarterly Revenue Connect Biopharma Holdings Ltd (ADR) Jun-2026 Quarterly Revenue is $3 Million which is growth of 5666.7% YoY.

  • NEGATIVE

    Quarterly Net Profit Connect Biopharma Holdings Ltd (ADR) Jun-2026 Quarterly Net Profit is $-17 Million which is growth of -34.0% YoY.

Connect Biopharma Holdings Ltd - ADR, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Jun '23Dec '22
Operating Rev.
2.80.200.10.71.224.1---
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
20.419.815.517.713.511.510.315.110.512.6-
Operating Profit
-17.6-19.6-15.5-17.7-13.4-11.5-9.6-13.913.7-12.6-
0.30.30.40.60.60.70.91.11.21.3---
Profit Before Tax
-17.2-19.4-15.1-17.1-12.8-10.2-8.8-12.814.9-8.7---
Tax
0.10.100.10.10.10.10.100---
⌄
-17.3-19.4-15.1-17.2-12.9-10.3-8.9-12.914.9-8.7---
Diluted NI Avail to Com Stockholders Ann.
-17.3-19.4-15.1-17.2-12.9-10.3-8.9-12.914.9-8.7---
Basic EPS
-0.3-0.3-0.3-0.3-0.2-0.2-0.2-0.20.3-0.2---
Diluted EPS After ExtraOrdinary
-----0.2-0.2--0.3-0.2---
Number Of Shares End
62.956.556.155.755.555.455.355.355.255.1-55.155
Net Income Continuing Discontinued Operations
-17.3-19.4-15.1-17.2-12.9-10.3-8.9-12.914.9-8.7---
Normalized Income
-16-18.2-14.2-16.3-12-9.3-7.5-9.415.4-7.4---
Interest Income
0.30.30.40.60.60.70.91.11.21.3---
Interest
-------------
Net Interest Income
0.30.30.40.60.60.70.91.11.21.3---
EBIT
-17.5-19.6-15.5-17.7-13.5-10.9-9.7-1413.7-9.9---
EBITDA
-17.4-19.5-15.3-17.5-13.3-10.8-9.5-13.914-9.8---
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0.20.20.20.20.20.20.200.30.2---
Profit From Continuing Operations
-17.3-19.4-15.1-17.2-12.9-10.3-8.9-14.416.4-8.7---
Normalized EBITDA
-17.4-19.4-15.4-17.5-13.3-11.3-9.5-13.814-12.5---
*All financials are in USD Million and price data in USD

Connect Biopharma Holdings Ltd (ADR) competitor comparison and performance snapshot within industry

Connect Biopharma Holdings Ltd (ADR) annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

  • NEGATIVE

    Annual Revenue Connect Biopharma Holdings Ltd (ADR) Dec-2025 Annual Revenue is $0 Million which is growth of -99.8% YoY.

  • NEGATIVE

    Annual Net Profit Connect Biopharma Holdings Ltd (ADR) Dec-2025 Annual Net Profit is $-55 Million which is growth of -255.0% YoY.

Connect Biopharma Holdings Ltd - ADR, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
 0.126
Cost Of Rev. Ann.
-
-
 -------
Gross Profit Ann.
-
-
 -------
Operating Exp. Ann.
-20.1%
14.7%
73.458.148.564.9113.897.529.316.2
Operating Profit Ann.
-
-
-70.4-58.1-22.5-64.9-113.8-97.5-29.3-16.2
15.3%
-
1.52.34.52.71.50.1-0.30.1
Other Exp. Ann.
-
-
 0.52.62.8-3-107.4-89.6-8.1
PBT Ann.
-
-
-68.8-55.3-15.4-59.4-115.2-204.8-119.3-24.1
Tax Ann.
-12.6%
-
0.20.20.20.10.30.3
⌄
-
-
-69-55.5-15.6-59.5-115.5-205-119.3-24.1
Diluted NI Avail to Com Stockholders Ann.
-
-
-69-55.5-15.6-59.5-115.5-205-119.3-24.1
EPS Ann.
-
-
 -1-0.3-1.1-2.2-3.9-2-0.4
Diluted EPS Ann.
-
-
 -1-0.3-1.1-2.2-3.9-2-0.4
Number Of Shares End
0.7%
0.8%
 56.155.3-5555.153.9-
Total Exp. Ann.
-20.1%
14.7%
 58.148.564.9113.897.529.316.2
Net Income Continuing Discontinued Operations Ann.
-
-
-69-55.5-15.6-59.5-115.5-205-119.3-24.1
Normalized Income Ann.
-
-
-64.7-51.7-8.7-59-103.5-88.5-24.3-15.5
Interest Income Ann.
12.9%
87.2%
1.52.34.52.71.60.10.10.2
Interest Ann.
-
-
 --00000
EBITDA Ann.
-
-
-69.6-56.9-19.2-61.1-118.6-201.6-112.7-24.4
Reconciled Cost Of Rev. Ann.
-
-
 -------
Reconciled Depr. Ann.
-11.2%
28.5%
0.70.70.7110.60.20.1
Profit From Continuing Operations Ann.
-
-
-69-55.5-15.6-59.4-115.2-204.8-119.3-24.1
Normalized EBITDA Ann.
-
-
-69.7-57.4-21.8-61.3-111.1-97.9-29.4-15.9
*All financials are in USD Million and price data in USD
Total Rev. Ann.
1Y CHG
-99.6%
Operating Exp. Ann.
1Y CHG
19.8%
2Y CAGR
-5.4%
3Y CAGR
-20.1%
5Y CAGR
14.7%

Connect Biopharma Holdings Ltd (ADR) balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Connect Biopharma Holdings Ltd (ADR) Dec-2025 Total Shareholders Fund is $42 Million which is growth of -54.5% YoY.

  • NEGATIVE

    Total Assets Connect Biopharma Holdings Ltd (ADR) Dec-2025 Total Assets is $56 Million which is growth of -44.6% YoY.

Connect Biopharma Holdings Ltd - ADR, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-31.7%
-19.5%
56.1101.3125.9175.7291.1166.153.3
⌄
-5.5%
-46.5%
14.19.124.916.718.8322.995.9
⌄
-35.8%
-
4292.2101159272.3-156.9-42.6
Total Capitalization Ann.
-35.8%
-
4292.2101159272.3-156.9-42.6
Tangible Assets Ann.
-35.5%
-
41.992.1101155.8268.8-156.9-42.6
Working Capital Ann.
-35.9%
-24.9%
37.388.596.7141.5257.2155.947.9
Invested Capital Ann.
-35.8%
-
4292.2101159272.3-156.9-42.6
Tangible Book Value Ann.
-35.5%
-
41.992.1101155.8268.8-156.9-42.6
Borrowings Ann.
20.5%
47.6%
0.70.20.50.40.10.10.1
Net Debt Ann.
-
-
-------
Share Issued Ann.
0.6%
1.7%
58.657.957.557.557.553.953.9
Number Of Shares End
0.7%
0.8%
56.155.3-5555.153.9-
*All financials are in USD Million and price data in USD
Total Assets Ann.
1Y CHG
-44.6%
2Y CAGR
-33.2%
3Y CAGR
-31.7%
5Y CAGR
-19.5%
Total Current Liabilities Ann.
1Y CHG
60%
2Y CAGR
-25.2%
3Y CAGR
-4.9%
5Y CAGR
18.6%
Total ShareHolders Funds Ann.
1Y CHG
-54.4%
2Y CAGR
-35.5%
3Y CAGR
-35.8%

Connect Biopharma Holdings Ltd (ADR) ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

  • NEUTRAL

    Book Value Per Share Connect Biopharma Holdings Ltd (ADR) Book Value Per Share is $0 which is growth of 0% YoY.

  • NEUTRAL

    ROE Connect Biopharma Holdings Ltd (ADR) ROE is 0% which is growth of 0% YoY.

Connect Biopharma Holdings Ltd - ADR, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--13.76%-39.46%-49.50%-89.69%-108.77%-45.26%
ROE Ann. %
-
-
--16.18%-45.77%-53.57%-355.18%--
ROIC %
-
-
--10.4-----
OPM Ann. %
-
-
-90,740.62%-86.24%-----
Inventory Turnover Ratio Ann.
-
-
-------
Asset Turnover Ann. %
-
-
-0.2-----
Working Capital Turnover Ann.
-
-
0.3
Quick Ratio Ann.
-
-
-11.24.99.814.92712.4
Current Ratio Ann.
-
-
-11.551015.327.813.2
Interest Coverage Ratio Ann.
-
-
---2,580.9-5,520-29,661-18,552-3,180.6
LT Debt To Equity Ann.
-
-
---
*All financials are in USD Million and price data in USD

Connect Biopharma Holdings Ltd (ADR) cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Connect Biopharma Holdings Ltd (ADR) Dec-2025 Cash From Operating Activity is $-51 Million which is growth of -116.9% YoY.

  • NEGATIVE

    Net Cash Flow Connect Biopharma Holdings Ltd (ADR) Dec-2025 Net Cash Flow is $-40 Million which is growth of -50.2% YoY.

Connect Biopharma Holdings Ltd - ADR, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
-
-
-51.2-23.6-47.9-98.5-85.5-25.6-12.9
-
81.3%
9.8-3.575.2-82.8-5.30.5-0.5
-
-62.1%
1.10.2-0.3-0.1206.5140.6-0.1
Cash Plus Cash Eqv. End Of Year Ann.
-21.7%
-24.4%
38.378.210679.8267.8154.644.2
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-40.3-26.827-181.4115.7115.5-13.4
Cash Plus Cash Eqv. Begin Of Year Ann.
-31.9%
10.6%
78.2105.779247.4158.547.357.4
Income Tax Paid Supplemental Data Ann.
-15.7%
-
0.30.10.10.5---
Interest Paid Supplemental Data Ann.
-
-
-------
Capex Ann.
-
-
-0.4-0.8-0.3-4.3-7.5-2.3-0.2
Issuance Of Capital Stock Ann.
-
-
--00224.6-
Issuance Of Debt Ann.
-
-
-------
Repayment Of Debt Ann.
-
-
---0.3-0.2-0.1-0.1-0.1
Repurchase Of Capital Stock Ann.
-
-
---0.6-
Free Cash Flow Ann.
-
-
-51.6-24.4-48.2-105.3-91.8-26.4-13.2
*All financials are in USD Million and price data in USD
Cash from Investing Act. Ann.
2Y CAGR
-63.9%
5Y CAGR
81.3%
Cash from Financing Act. Ann.
1Y CHG
450%
5Y CAGR
-62.1%